返回 
加入收藏
川芎嗪注射液、α-酮酸联合左旋氨氯地平治疗慢性肾功能衰竭的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 川芎嗪注射液、α-酮酸联合左旋氨氯地平治疗慢性肾功能衰竭的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察川芎嗪注射液、α-酮酸联合左旋氨氯地平治疗慢性肾功能衰竭的疗效和安全性。方法：92例慢性肾功能衰竭患者随机分为观察组（46例）和对照组（46例）。所有患者均给予电解质、维生素及氨基酸、低盐低脂、降糖降脂、抗感染及纠正贫血等常规对症治疗。在此基础上，对照组患者口服复方α-酮酸片8片，每日3次+苯磺酸左旋氨氯地平片1片，每日1次。观察组患者在对照组治疗的基础上给予盐酸川穹嗪注射液150 mg，加入5％葡萄糖250 ml中，静脉滴注，每日1次。两组疗程均为3个月。观察两组患者的临床疗效，治疗前后尿素氮（BUN）、血肌酐（Scr）、血清胱抑素（CysC）、低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、三酰甘油 （TG）水平及不良反应发生情况。结果：观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者BUN、Scr、CysC、LDL-C、TC、TG比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者BUN、Scr、LDL-C、TC、TG均显著低于同组治疗前，且观察组低于对照组，CysC显著高于同组治疗前，且观察组高于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，川芎嗪注射液、α-酮酸联合左旋氨氯地平治疗慢性肾功能衰竭的疗效显著，可改善肾功能，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy and safety of Ligustrazine injection， α-ketoacid combined with levamlodipine in the treatment of chronic renal failure. METHODS： 92 patients with chronic renal failure were randomly divided into observation group （46 cases） and control group （46 cases）. All patients received electrolyte， vitamins and essential amino acid， low salt， low fat， hypoglycemic and hypolipemic， anti-infection， correcting anemia and other conventional symptomatic treatment. Based on it， control group received 8 Compound α-ketoacid tablets， 3 times a day + 1 Benzenesulfonic acid levamlodipine tablet， once a day. Observation group additionally received 150 mg Ligustrazine hydrochloride injection， adding into 250 ml 5％ Glucose injection， intravenous infusion， once a day. The treatment course for both groups was 3 months. Clinical efficacy， and urea nitrogen （BUN）， serum creatinine （Scr）， serum cystatin （CysC）， low-density lipoprotein cholesterol （LDL-C）， total cholesterol （TC）， triglyceride （TG） levels before and after treatment and the incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， the difference was statistically significant （P＜0.05）. Before treatment， there were no significant differences in the BUN， Scr， CysC， LDL-C， TC and TG between 2 groups （P＞0.05）. After treatment， BUN， Scr， LDL-C， TC and TG in 2 groups were significantly lower than before， and observation group was lower than control group， CysC was significantly higher than before， and observation group was higher than control group， the differences were statistically significant （P＜0.05）. And there was no significant difference in the incidence of adverse reactions （P＞0.05）. CONCLUSIONS： Based on conventional treatment， Ligustrazine injection， α-ketoacid combined with levamlodipine show obvious efficacy in the treatment of chronic renal failure， they can improve the renal functions， with good safety. |
| 期刊： | 2016年第27卷第24期 |
| 作者： | 杨雪莲，李列平 |
| AUTHORS： | YANG Xuelian，LI Lieping |
| 关键字： | 川芎嗪注射液；α-酮酸；左旋氨氯地平；慢性肾功能衰竭；疗效；安全性 |
| KEYWORDS： | Ligustrazine injection； α-ketoacid； Levamlodipine； Chronic renal failure； Efficacy； Safety |
| 阅读数： | 247 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
